• Molecular Partners disclosed new preclinical data for Switch-DARPin T cell engager MP0632, with results already presented in three posters at AACR 2026.
• MP0632 produced tumor regression in models designed to reflect dual-target expression, with limited activity in single-target settings, supporting a potentially wider safety margin.
• Separate poster data outlined MP0712, a DLL3-targeted Radio-DARPin now in an ongoing US Phase 1/2a trial, with properties intended to drive higher tumor uptake.
• Early patient imaging from a named-patient program was cited as consistent with preclinical tumor targeting for MP0712, supporting further clinical evaluation in DLL3-expressing cancers.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Molecular Partners AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604191200PRIMZONEFULLFEED9692685) on April 19, 2026, and is solely responsible for the information contained therein.